Targeting Microglial TREM2 to Shift ALS
- The biological rationale for modulating microglial TREM2 with VHB937 to potentially enhance protective microglial functions and support motor neuron health in ALS
- Key design features of the ASTRALS Phase 2 trial, including the 40 week double blind period followed by an open label extension to assess long term safety and functional outcomes
- Early clinical observations from the ongoing study and how proximal signals will inform future ALS therapeutic strategies
- The role of functional endpoints like ventilator free survival and ALSFRS R changes in interpreting disease modifying potential in a TREM2 targeted ALS therapy